Clinical trials: Induced Pluripotent Stem Cell (Ips Cell)
Systemic Sclerosis (SSc)
Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed. The primary objective is to generate, via the SAFE-IPS platform, 8 iPSC lines derived from blood samples taken from: Two…
- Trial name
- hiPSSS (NCT07650565)
- Testing
- Blood Sample Collection
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Retinitis Pigmentosa
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA)…
- Trial name
- NCT06891885
- Testing
- DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sumitomo Pharma America, Inc.
Severe Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA)
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
Asthma is severe when it cannot be controlled with maximum-dose inhaled therapies while management of comorbidities and other precipitating or aggravating factors has been optimized.
- Trial name
- MOSAIC (NCT05616338)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Univentricular Heart, Congenital Heart Disease
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease.
- Conditions
- Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT05647213
- Testing
- iPSC-CL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HeartWorks, Inc.
Coronary Artery Disease
Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells
This research is being done to understand how changes in DNA may put people at risk for developing coronary artery disease. Stem cells will be made using cells from blood and/or skin biopsy samples.
- Trial name
- iPSC (NCT01517425)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Scripps Translational Science Institute
Genetic Disease
Developing Protocols for Modelling of Genetic Diseases Using Induced Pluripotent Stem Cells
Recent advances have shown that cells from human blood, skin and urine samples can be reprogrammed to become stem cells. These are called induced Pluripotent Stem Cells (iPSCs) and share many characteristics with embryonic stem…
- Trial name
- NCT03612310
- Testing
- Skin biopsy/Urine Collection/Blood Sample Collection
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Sapna Vyas
Age Related Macular Degeneration (AMD)
Production of iPSC Derived RPE Cells for Transplantation in AMD
No treatments exist for Age-related Macular Degeneration (AMD) when there is cell loss such as in late wet AMD or dry AMD. The differentiation of RPE cells from patient derived iPSC will offer valuable source of tissue for…
- Trial name
- NCT02464956
- Volunteers
- 3 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Marfan's Syndrome
Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells
Medical researchers of National Heart Centre Singapore will carry out a state-of-the-art study that examines the possibility of changing patients' own cells into multi-functional and potent stem cells called iPS cells.
- Trial name
- NCT02815072
- Testing
- Skin biopsy
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Heart Centre Singapore
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication.
- Trial name
- PEAR-iPSC (NCT01943383)
- Testing
- iPSC
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Florida
System Lupus Erythematosus, Systemic Sclerosis (SSc)
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
This study primarily involves the use of BCT301, an anti-CD19 Chemically induced pluripotent stem cell (CiPSC)-derived CAR-iT cells, for the treatment of patients with refractory autoimmune diseases, aiming to evaluate its…
- Conditions
- System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome
- Trial name
- NCT07301164
- Testing
- BCT301
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Pulmonary Disease, Chronic Obstructive
Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS)
The aim of this interventional, cross-sectional and pathophysiological experimental study is to evaluate the potential of a patient's induced pluripotent stem (iPS) cells, used prior to the re-differentiation stage, to enable ex…
- Trial name
- RepCOPDiPS (NCT06755008)
- Testing
- bronchial fibroscopy
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
Regenerative Medicine, Induced Pluripotent Stem Cells (iPSC) Production
SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future
The objective of the study is to establish the first French hospital-based Good Manufacturing Practice (GMP)-compliant platform for the production of clinical-grade induced pluripotent stem cells (iPSCs) for future regenerative…
- Trial name
- SAFE-iPS (NCT07735559)
- Testing
- Blood Collection for iPSC Generation
- Where
- France
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Heart Failure, Ischemic Heart Disease
A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)
The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.
- Trial name
- LAPiS (NCT04945018)
- Testing
- HS-001 CS, HS-001-D needle, HS-001-D Adaptor
- Where
- 8 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Heartseed Inc.
Thrombocytopenia
A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation
A multicenter open-label study with dose-escalation and multiple expansion cohorts, aimed at evaluating the safety and preliminary efficacy of IPSC-derived platelets in patients with thrombocytopenia caused by allogeneic…
- Trial name
- NCT07905144
- Testing
- iPSC-derived platelets
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Parkinson's Disease
A Clinical Trial of Parkinson's Disease Treatment by HiPSCs Derived Dopaminergic Neural Precursor Cells
XellSmart Biomedical (Suzhou) Co., Ltd. has closely collaborated with Shanghai East Hospital(East Hospital Affiliated To Tongji University) , using iPSC seed cells, on the development and establishment of a dopaminergic neural…
- Trial name
- hiPSC-DAP (NCT06145711)
- Testing
- hiPSC-DAP
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- Shanghai East Hospital
Parkinson Disease
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain.
- Trial name
- NCT07212088
- Testing
- ALC01 therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- iCamuno Biotherapeutics Ltd.
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell…
- Conditions
- R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
- Trial name
- ELiPSE-1 (NCT05336409)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 16 sites in United States
- Volunteers
- 28 people
- Sponsor
- Century Therapeutics, Inc.
Glioma
Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma
The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).
- Trial name
- GLIOMANOID (NCT03971812)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille